Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

  • Filters activated: Cancer. Clear all to show 12 items.
1.

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.

Widman DG, Gornisiewicz S, Shacham S, Tamir S.

PLoS One. 2018 Oct 17;13(10):e0200043. doi: 10.1371/journal.pone.0200043. eCollection 2018.

2.

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Sadowski AR, Gardner HL, Borgatti A, Wilson H, Vail DM, Lachowicz J, Manley C, Turner A, Klein MK, Waite A, Sahora A, London CA.

BMC Vet Res. 2018 Aug 24;14(1):250. doi: 10.1186/s12917-018-1587-9.

3.

In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.

Grayton JE, Miller T, Wilson-Robles H.

Vet Comp Oncol. 2017 Dec;15(4):1455-1467. doi: 10.1111/vco.12289. Epub 2017 Jan 30. No abstract available.

PMID:
28133930
4.

A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.

Tajiri N, De La Peña I, Acosta SA, Kaneko Y, Tamir S, Landesman Y, Carlson R, Shacham S, Borlongan CV.

CNS Neurosci Ther. 2016 Apr;22(4):306-15. doi: 10.1111/cns.12501. Epub 2016 Feb 4.

5.

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere ML, Baloglu E, Klebanov B, Donovan S, Del Alamo D, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Jan 12;7(2):1863-77. doi: 10.18632/oncotarget.6495.

6.

Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C.

J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. Review.

7.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

8.

Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Perwitasari O, Johnson S, Yan X, Howerth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA.

J Virol. 2014 Sep 1;88(17):10228-43. doi: 10.1128/JVI.01774-14. Epub 2014 Jun 25.

9.

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.

PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585. eCollection 2014.

Supplemental Content

Loading ...
Support Center